Leaflet: information for the user
Zonisamide Teva 50 mg hard capsules EFG
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
- Keep this leaflet, as you may need to read it again.
- If you have any questions, consult your doctor or pharmacist.
- This medicine has been prescribed for you only, and you must not give it to others even if they have the same symptoms as you, as it may harm them.
- If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. See section 4.
1. What Zonisamide Teva is and what it is used for
2. What you need to know before you start taking Zonisamide Teva
3. How to take Zonisamide Teva
4. Possible side effects
5. Storage of Zonisamide Teva
6. Contents of the pack and additional information
Zonisamida Teva contains the active ingredient zonisamida, and is used as an antiepileptic.
Zonisamida is used to treat seizures that affect a part of the brain (partial seizures), which may or may not be followed by seizures that affect the entire brain (secondary generalization).
Zonisamida may be used:
Do not take Zonisamida Teva:
Warnings and precautions
Zonisamida belongs to a group of medicines (sulfonamides) that can cause severe allergic reactions, severe rashes, and blood disorders, which very rarely can causedeath(see section 4. Possible side effects).
There have been cases of severe rashes associated with zonisamida therapy, including cases of Stevens-Johnson syndrome. |
The use of zonisamida may cause high levels of ammonia in the blood, which could change brain function, especially if you are also taking other medicines that can increase ammonia levels (e.g., valproate), if you have a genetic disorder that causes too much ammonia in the body (urea cycle disorder), or if you have liver disorders. Inform your doctor immediately if you feel drowsy or confused in an unusual way.
Consult your doctor or pharmacist before starting to take Zonisamida Teva if you:
If any of these statements apply to you, inform your doctor before taking Zonisamida Teva.
Children and adolescents
Consult your doctor about the following risks:
Prevention of heatstroke and dehydration in children Zonisamida can cause your child to sweat less or develop heatstroke; this can cause brain damage and death if not treated. Children are the most vulnerable group, especially on hot days. While your child is taking zonisamida:
carbonic anhydrase inhibitors (e.g.: topiramate and acetazolamide) and anticholinergics (such as clomipramine, hydroxyzine, diphenhydramine, haloperidol, imipramine, and oxybutynin). If your child's skin is very hot with little or no sweating, the child feels confused or develops muscle cramps, or their heart rate or breathing is rapid:
|
Do not administer this medicine to childrenunder 6 yearsas it is not known if the possible benefits outweigh the risks in this age group.
Use of Zonisamida Teva with other medicines
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medicine.
Taking Zonisamida Teva with food and drinks
Zonisamida Teva can be taken with or without food.
Pregnancy, breastfeeding, and fertility
Women of childbearing age should use effective contraceptive measures during treatment with zonisamida and for one month after stopping zonisamida.
If you intend to become pregnant, talk to your doctor before stopping your contraceptives and before becoming pregnant about the possibility of switching to other suitable treatments. If you are or think you may be pregnant, inform your doctor or pharmacist immediately. Do not stop treatment without consulting your doctor.
You should only take zonisamida during pregnancy if your doctor advises it. Research has shown a higher risk of birth defects in children of women taking antiepileptic medicines.
The risk of birth defects or neurological developmental disorders (brain development problems) for your child after taking zonisamida during pregnancy is unknown. A study showed that children whose mothers took zonisamida during pregnancy were smaller than expected for their age at birth, compared to children whose mothers were treated with lamotrigine monotherapy. Make sure you are fully informed about the risks and benefits of using zonisamida for epilepsy during pregnancy.
Do not breastfeed while taking zonisamida or for one month after stopping zonisamida.
There are no clinical data on the effects of zonisamida on human fertility. Animal studies have shown changes in fertility parameters.
Driving and operating machinery
Zonisamida may affect your concentration, reaction time, and may cause drowsiness, especially at the start of treatment or after increasing the dose. If zonisamida affects you in this way, be especially careful when driving or operating machinery.
Sodium
This medicine contains less than 1 mmol of sodium (23 mg) per hard capsule; it is essentially “sodium-free”.
Follow exactly the administration instructions of this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
The recommended dose in adults is
If you take Zonisamida Teva alone:
If you take Zonisamida Teva with other antiepileptic medications:
Use in children (6 to 11 years old) and adolescents (12 to 17 years old) who weigh at least 20 kg:
Example: a child weighing 25 kg should take 25 mg once a day during the first week, and then the daily dose should be increased by 25 mg at the beginning of each week until the daily dose of 150 to 200 mg is reached.
If you estimate that the action of Zonisamida Teva is too strong or too weak, inform your doctor or pharmacist.
If you take more Zonisamida Teva than you should
Go to the doctor immediately. Bring the medication packaging with you. You can also call the Toxicology Information Service, phone 91 562 04 20 indicating the medication and the amount taken. You may feel drowsy and may lose consciousness. You may also feel like vomiting, have stomach pain, muscle spasms, eye movement, feel like fainting, have a slow heart rate and decreased respiratory rate and renal function. Do not drive.
If you forgot to take Zonisamida Teva
If you interrupt treatment with Zonisamida Teva
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Zonisamide belongs to a group of medicines (sulfonamides) that can cause severe allergic reactions, severe rashes, and blood disorders, which very rarely can cause death.
Immediately contact your doctor if you:
Immediately contact your doctor as soon as possible if you:
Your doctor may decide that you should stop taking Zonisamide Teva.
The most commonly reported side effects of zonisamide are all mild in nature. They occur during the first month of treatment and often decrease as treatment continues. In children aged 6 to 17 years, the side effects were consistent with those described below, except for the following: pneumonia, dehydration, decreased sweating (frequent), and abnormal liver enzymes (infrequent).
Very common side effects: may affect more than 1 in 10 people
Common side effects: may affect up to 1 in 10 people
Rare side effects: may affect up to 1 in 100 people
Very rare side effects: may affect up to 1 in 10,000 people
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the blister pack and on the outer packaging after CAD. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Do not use this medication if you observe any sign of deterioration in the capsules, blister pack, or box, or any visible sign of deterioration in the medication. Return the packaging to your pharmacist.
Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications that you do not need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications that you do not need. By doing so, you will help protect the environment.
Zonisamide Teva 50 mg hard capsules EFG contain 50 mg of zonisamide.
Appearance of the product and contents of the package
Zonisamide Teva 50 mg hard capsules: hard gelatin capsule size No. 3, approximately 16 mm x 6 mm, with a gray cap and a white body, filled with a white or off-white granulate, printed with "50" on the body.
The hard capsules of Zonisamide Teva 50 mg are packaged in blisters of 7, 14, 28, 30, 56, 60, or 100 hard capsules.
Only some package sizes may be commercially available.
Marketing authorization holder and responsible manufacturer
Marketing authorization holder
Teva Pharma S.L.U.
C/Anabel Segura, 11 Edificio Albatros B, 1st Floor
28108 Alcobendas, Madrid
Responsible manufacturer
TEVA Gyógyszergyár Zrt.
Pallagi út 13
4042 Debrecen
Hungary
or
Teva Operations Poland Sp. z.o.o
ul. Mogilska 80, Krakow
31-546
Poland
or
Merckle GmbH
Ludwig-Merckle-Straße 3,
89143 Blaubeuren
Germany
or
Teva Pharma B.V.
Swensweg 5, Haarlem
2031 GA
Netherlands
This medicinal product is authorized in the Member States with the following names:
Germany: Zonisamid-ratiopharm 50 mg Hartkapseln
Denmark: Zonisamide Teva
Spain: Zonisamide Teva 50 mg hard capsules EFG
France: Zonisamide Teva 50 mg gélule
Netherlands: Zonisamide Teva 50mg harde capsules
Portugal: Zonisamide Ratiopharm
Sweden: Zonisamide Teva
United Kingdom: Zonisamide Ratiopharm 50 mg Capsules, Hard
Last review date of this leaflet:May 2023
For detailed information about this medicinal product, please visit the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
You can access detailed and updated information about this medicinal product by scanning the QR code included in the carton with your smartphone. You can also access this information at the following internet address:https://cima.aemps.es/cima/dochtml/p/80452/P_80452.html
QR code + URL
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.